Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 18, 2021 - Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the ”Company”) Board of Directors has today, pursuant to the authorization granted by the extraordinary general meeting held on May 14, 2021 (“the EGM”), resolved on an issue of shares of a maximum of 62,524,474 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The subscription price in the Rights Issue is SEK 6.40 per share. If the Rights Issue is fully subscribed, the Company will receive approximately SEK 400 million